JP2018064568A5 - - Google Patents

Download PDF

Info

Publication number
JP2018064568A5
JP2018064568A5 JP2017223489A JP2017223489A JP2018064568A5 JP 2018064568 A5 JP2018064568 A5 JP 2018064568A5 JP 2017223489 A JP2017223489 A JP 2017223489A JP 2017223489 A JP2017223489 A JP 2017223489A JP 2018064568 A5 JP2018064568 A5 JP 2018064568A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
truncated
nucleic acid
composition according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017223489A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018064568A (ja
JP6767347B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018064568A publication Critical patent/JP2018064568A/ja
Publication of JP2018064568A5 publication Critical patent/JP2018064568A5/ja
Application granted granted Critical
Publication of JP6767347B2 publication Critical patent/JP6767347B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017223489A 2015-03-02 2017-11-21 Ｐｄ−ｌ１によって誘導される免疫寛容の低減 Active JP6767347B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562126804P 2015-03-02 2015-03-02
US62/126,804 2015-03-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017546893A Division JP6336684B2 (ja) 2015-03-02 2016-03-01 Ｐｄ−ｌ１によって誘導される免疫寛容の低減

Publications (3)

Publication Number Publication Date
JP2018064568A JP2018064568A (ja) 2018-04-26
JP2018064568A5 true JP2018064568A5 (cg-RX-API-DMAC7.html) 2019-02-21
JP6767347B2 JP6767347B2 (ja) 2020-10-14

Family

ID=56848306

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017546893A Active JP6336684B2 (ja) 2015-03-02 2016-03-01 Ｐｄ−ｌ１によって誘導される免疫寛容の低減
JP2017223489A Active JP6767347B2 (ja) 2015-03-02 2017-11-21 Ｐｄ−ｌ１によって誘導される免疫寛容の低減

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017546893A Active JP6336684B2 (ja) 2015-03-02 2016-03-01 Ｐｄ−ｌ１によって誘導される免疫寛容の低減

Country Status (11)

Country Link
US (4) US9572837B2 (cg-RX-API-DMAC7.html)
EP (2) EP3089761B1 (cg-RX-API-DMAC7.html)
JP (2) JP6336684B2 (cg-RX-API-DMAC7.html)
KR (1) KR102133857B1 (cg-RX-API-DMAC7.html)
CN (2) CN107073138B (cg-RX-API-DMAC7.html)
AU (1) AU2016228080B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017018770A2 (cg-RX-API-DMAC7.html)
CA (1) CA2976684C (cg-RX-API-DMAC7.html)
RU (1) RU2688692C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201706947TA (cg-RX-API-DMAC7.html)
WO (1) WO2016138846A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
KR102763121B1 (ko) 2015-02-06 2025-02-04 내셔널 유니버시티 오브 싱가포르 치료적 면역 세포의 효능의 향상 방법
WO2016138846A1 (en) * 2015-03-02 2016-09-09 Shanghai Sidansai Biotechnology Co., Ltd Reducing immune tolerance induced by pd‐l1
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
CA2997551A1 (en) 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
JP7123794B2 (ja) 2015-12-09 2022-08-23 メモリアル スローン ケタリング キャンサー センター 免疫細胞組成物及びそれを使用する方法
EP3433269B1 (en) 2016-03-23 2023-09-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
EP3988111A1 (en) 2016-04-01 2022-04-27 Innovative Cellular Therapeutics Holdings, Ltd. Use of chimeric antigen receptor modified cells to treat cancer
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN109863242A (zh) 2016-08-30 2019-06-07 纪念斯隆-凯特林癌症中心 用于治疗病毒感染和其它感染的免疫细胞组合物和使用方法
WO2018064921A1 (en) * 2016-10-06 2018-04-12 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
WO2018067993A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
NZ752984A (en) 2016-11-22 2026-03-27 Nat Univ Singapore Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
CN108148862B (zh) * 2016-12-05 2019-03-08 上海优卡迪生物医药科技有限公司 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
US20190358263A1 (en) 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3592368A1 (en) * 2017-03-08 2020-01-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
MX2020007357A (es) * 2017-09-26 2021-08-11 Longwood Univ Reporte de antígeno quimérico específico de pd1 como una inmunoterapia.
CN109836493A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向cd19的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
US10561686B2 (en) * 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
US12312416B2 (en) 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
EP3784776A4 (en) 2018-05-23 2022-01-26 National University of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US20210379149A1 (en) * 2018-10-25 2021-12-09 Innovative Cellular Therapeutics Holdings, Ltd. Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
WO2020116686A1 (ko) 2018-12-06 2020-06-11 고려대학교 산학협력단 인간 항-antxr 키메라 항원 수용체 및 이의 용도
CN109971842A (zh) * 2019-02-15 2019-07-05 成都美杰赛尔生物科技有限公司 一种检测CRISPR-Cas9脱靶效应的方法
WO2020172555A1 (en) * 2019-02-21 2020-08-27 Regents Of The University Of Minnesota Genetically modified gamma delta t cells and methods of making and using
AU2020232216B2 (en) * 2019-03-01 2025-09-25 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a PD-1 ectodomain
JP2022531814A (ja) * 2019-03-12 2022-07-12 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ 改変細胞の増幅およびその応用
US11739136B2 (en) * 2019-03-18 2023-08-29 Innovative Cellular Therapeutics Holdings, Ltd. Inducible dominant negative PD-1 and uses in adoptive cell therapy
CN109868263A (zh) * 2019-03-29 2019-06-11 深圳精准医疗科技有限公司 重组单纯疱疹病毒及其制备方法和应用、重组载体的构建方法及其应用
SG11202112676VA (en) * 2019-05-16 2021-12-30 Memorial Sloan Kettering Cancer Center Mesothelin cars and uses thereof
CN110423767A (zh) * 2019-07-12 2019-11-08 华东师范大学 表达可溶性pd-1的嵌合抗原受体car基因及应用
CN110592140A (zh) * 2019-09-30 2019-12-20 王清路 Pd-1基因缺陷型pd-1-cart细胞制剂的制法
US20210137983A1 (en) * 2019-11-08 2021-05-13 Innovative Cellular Therapeutics Holdings, Ltd. Nk cell expansion and uses thereof
EP4491235A3 (en) * 2019-11-26 2025-03-26 ImmunityBio, Inc. Primary nk car constructs and methods
CN115210252A (zh) 2020-02-04 2022-10-18 西雅图儿童医院（Dba西雅图儿童研究所） 抗二硝基苯酚的嵌合抗原受体
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
JP7198302B2 (ja) * 2021-03-08 2022-12-28 一般財団法人 化学物質評価研究機構 Ｐｄ－１を介した免疫チェックポイント阻害剤の生物活性試験法
US20230227779A1 (en) 2022-01-19 2023-07-20 Innovative Cellular Therapeutics Holdings, Ltd. Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor Microenvironment
WO2025184170A1 (en) * 2024-02-27 2025-09-04 Overt Bio, Inc. Methods and compositions for improving t cell function in an immunosuppressive environment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
EP1425421A2 (en) * 2001-09-07 2004-06-09 Everygene AB Polymorphisms of pd-1
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
US9688740B2 (en) * 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
CA2861491C (en) * 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
BR112014029417B1 (pt) * 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
AU2013329186B2 (en) * 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CN113684185A (zh) * 2013-02-26 2021-11-23 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
WO2014145252A2 (en) * 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
KR102164455B1 (ko) 2013-05-08 2020-10-13 삼성전자주식회사 콘텐트 제공 방법, 콘텐트 제공 장치 및 그 콘텐트 제공 시스템
WO2014183066A2 (en) * 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
ES2857226T3 (es) 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
PT3177640T (pt) * 2014-08-08 2020-08-31 Univ Leland Stanford Junior Agentes pd-1 de alta afinidade e métodos de utilização
WO2016138846A1 (en) 2015-03-02 2016-09-09 Shanghai Sidansai Biotechnology Co., Ltd Reducing immune tolerance induced by pd‐l1
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
CA2997551A1 (en) 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
JP7123794B2 (ja) 2015-12-09 2022-08-23 メモリアル スローン ケタリング キャンサー センター 免疫細胞組成物及びそれを使用する方法
US20220265708A1 (en) 2018-01-11 2022-08-25 Innovative Cellular Therapeutics, Inc. Modified Cell Expansion and Uses Thereof
US20210379149A1 (en) 2018-10-25 2021-12-09 Innovative Cellular Therapeutics Holdings, Ltd. Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy

Similar Documents

Publication Publication Date Title
JP2018064568A5 (cg-RX-API-DMAC7.html)
JP2017518037A5 (cg-RX-API-DMAC7.html)
RU2017130985A (ru) Фармацевтическая композиция и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека
JP2016532693A5 (cg-RX-API-DMAC7.html)
Lürick et al. Multivalent Rab interactions determine tether-mediated membrane fusion
WO2018187613A3 (en) Anti-icos agonist antibodies and uses thereof
JP2015212284A5 (cg-RX-API-DMAC7.html)
JP2020114264A5 (cg-RX-API-DMAC7.html)
JP2018505139A5 (cg-RX-API-DMAC7.html)
JP2020529841A5 (cg-RX-API-DMAC7.html)
IL275497B (en) Serum proteins with type iii fibronectin binding domains
JP2017522862A5 (cg-RX-API-DMAC7.html)
JP2018529327A5 (cg-RX-API-DMAC7.html)
JP2019506841A5 (cg-RX-API-DMAC7.html)
JP2017537622A5 (cg-RX-API-DMAC7.html)
FI3596116T3 (fi) Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
JP2019508444A5 (cg-RX-API-DMAC7.html)
JP2020517294A5 (cg-RX-API-DMAC7.html)
WO2015104406A3 (en) Multi-specific polypeptide useful for localized tumor immunomodulation
ZA201607061B (en) Transgene genetic tags and methods of use
IL292650B1 (en) COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
JP2021531265A5 (cg-RX-API-DMAC7.html)
JP2009201525A5 (cg-RX-API-DMAC7.html)
JP2019524100A5 (cg-RX-API-DMAC7.html)
BR112014008849A2 (pt) receptores quiméricos de antígeno anti-cd22